Merck Tbk - Asset Resilience Ratio
Merck Tbk (MERK) has an Asset Resilience Ratio of 6.75% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Merck Tbk debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2024)
This chart shows how Merck Tbk's Asset Resilience Ratio has changed over time. See what is Merck Tbk's book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Merck Tbk's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Merck Tbk.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rp0.00 | 0% |
| Short-term Investments | Rp68.00 Billion | 6.75% |
| Total Liquid Assets | Rp68.00 Billion | 6.75% |
Asset Resilience Insights
- Limited Liquidity: Merck Tbk maintains only 6.75% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Merck Tbk Industry Peers by Asset Resilience Ratio
Compare Merck Tbk's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Daihan Pharmaceutical Co.Ltd
KQ:023910 |
Drug Manufacturers - Specialty & Generic | 11.95% |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA |
Drug Manufacturers - Specialty & Generic | 16.92% |
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999 |
Drug Manufacturers - Specialty & Generic | 5.22% |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538 |
Drug Manufacturers - Specialty & Generic | 2.69% |
|
Zhejiang Xianju Pharmaceutical Co Ltd
SHE:002332 |
Drug Manufacturers - Specialty & Generic | 6.02% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Hainan Honz Pharmaceutical Co
SHE:300086 |
Drug Manufacturers - Specialty & Generic | 0.27% |
|
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111 |
Drug Manufacturers - Specialty & Generic | 7.85% |
Annual Asset Resilience Ratio for Merck Tbk (2000–2024)
The table below shows the annual Asset Resilience Ratio data for Merck Tbk.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 2.93% | Rp28.00 Billion ≈ $1.64 Million |
Rp956.94 Billion ≈ $56.07 Million |
+0.91pp |
| 2023-12-31 | 2.02% | Rp19.31 Billion ≈ $1.13 Million |
Rp957.81 Billion ≈ $56.12 Million |
-5.66pp |
| 2022-12-31 | 7.67% | Rp79.61 Billion ≈ $4.67 Million |
Rp1.04 Trillion ≈ $60.80 Million |
+2.37pp |
| 2021-12-31 | 5.30% | Rp54.40 Billion ≈ $3.19 Million |
Rp1.03 Trillion ≈ $60.14 Million |
-5.07pp |
| 2020-12-31 | 10.37% | Rp96.40 Billion ≈ $5.65 Million |
Rp929.90 Billion ≈ $54.49 Million |
+2.10pp |
| 2019-12-31 | 8.27% | Rp74.50 Billion ≈ $4.37 Million |
Rp901.06 Billion ≈ $52.80 Million |
-- |
| 2017-12-31 | 0.00% | Rp0.00 ≈ $0.00 |
Rp847.01 Billion ≈ $49.63 Million |
-- |
| 2016-12-31 | 13.31% | Rp99.00 Billion ≈ $5.80 Million |
Rp743.93 Billion ≈ $43.59 Million |
+11.01pp |
| 2005-12-31 | 2.29% | Rp5.00 Billion ≈ $292.98K |
Rp218.03 Billion ≈ $12.78 Million |
-3.40pp |
| 2004-12-31 | 5.69% | Rp11.41 Billion ≈ $668.59K |
Rp200.47 Billion ≈ $11.75 Million |
-5.96pp |
| 2003-12-31 | 11.65% | Rp23.33 Billion ≈ $1.37 Million |
Rp200.33 Billion ≈ $11.74 Million |
-7.11pp |
| 2002-12-31 | 18.75% | Rp32.32 Billion ≈ $1.89 Million |
Rp172.34 Billion ≈ $10.10 Million |
+5.13pp |
| 2001-12-31 | 13.62% | Rp22.17 Billion ≈ $1.30 Million |
Rp162.72 Billion ≈ $9.53 Million |
+12.47pp |
| 2000-12-31 | 1.16% | Rp1.50 Billion ≈ $87.89K |
Rp129.68 Billion ≈ $7.60 Million |
-- |
About Merck Tbk
PT Merck Tbk engages in the manufacture and sale of pharmaceutical products in Indonesia and internationally. The company operates through Biopharma, Consumer Health, and Others segments. It offers health care products in the areas of cardiovascular, metabolic, oncology, endocrinology, fertility, and neurodegenerative diseases, as well as general medicines. The company also engages in research an… Read more